RxDoctor Payments Data

Susan Tucker, MD

Internal Medicine · Tallmadge, OHNPI 1982961751

Payments from drug & device makers

$1,816in general payments, 2019–2025

Across 101 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$696
  • Novo Nordisk$199
  • Bayer$129
  • Amgen$120
  • Boehringer Ingelheim$96
  • Astellas Pharma US Inc$82
  • plus $495 from 19 others

What the payments were for

  • Food & beverage$1,816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,816 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$69,445
Medicare patients
201
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$107,965
JardianceEmpagliflozin106$99,591
OzempicSemaglutide50$65,724
MyrbetriqMirabegron77$56,656
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$52,163
TrulicityDulaglutide22$36,393
ProliaDenosumab15$26,070
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$24,215
RybelsusSemaglutide14$22,868
XareltoRivaroxaban20$15,584
Tresiba Flextouch U-200Insulin Degludec15$12,649
Breo ElliptaFluticasone/Vilanterol20$12,073
Praluent PenAlirocumab17$11,996
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$7,987
BelsomraSuvorexant13$6,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$107,965100 claims
Boehringer IngelheimJardiance$96$99,591106 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$43$93,590118 claims
Novo NordiskOzempic, Rybelsus$199$88,59364 claims
Astellas Pharma US IncMyrbetriq$82$56,65677 claims
Lilly USA, LLCTrulicity$31$36,39322 claims
AmgenProlia$120$26,07015 claims
Johnson & JohnsonXarelto$26$15,58420 claims
MerckBelsomra$13$6,47413 claims
AbbVieSynthroid$696$2,02978 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Tallmadge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →